An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AIM ImmunoTech announces the release of the next CEO Corner segment featuring an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need by Thomas Equels, the Chief Executive Officer.
AIM ImmunoTech annuncia il rilascio del prossimo segmento dell'Angolo del CEO con una panoramica sull'Adenocarcinoma Pancreatico Localmente Avanzato e la necessità insoddisfatta, presentata da Thomas Equels, Amministratore Delegato.
AIM ImmunoTech anuncia la publicación del próximo segmento de la Esquina del CEO, que presenta una visión general del Adenocarcinoma de Páncreas Localmente Avanzado y la necesidad no cubierta por Thomas Equels, el Director Ejecutivo.
AIM ImmunoTech는 최고 경영자인 Thomas Equels가 소개하는 지역적으로 진행된 췌장 선암과 충족되지 않은 의료 필요에 대한 개요를 특징으로 하는 다음 CEO 코너 세그먼트의 출시를 발표합니다.
AIM ImmunoTech annonce la sortie du prochain segment du Coin du PDG présentant un aperçu de l'Adénocarcinome Pancréatique Localement Avancé et du besoin non satisfait par Thomas Equels, le Directeur Général.
AIM ImmunoTech kündigt die Veröffentlichung des nächsten CEO-Eckensegments an, das einen Überblick über lokal fortgeschrittenes Pankreasadenokarzinom und den ungedeckten Bedarf von Thomas Equels, dem Geschäftsführer, bietet.
Positive
None.
Negative
None.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
